Why do we not risk assess?

The problem is often below the surface

I have recently been thinking about difficulties companies face with Quality Risk Management. It seems to me that businesses can de-prioritise quality inspections because the regulatory requirements and the business’ objectives do not, on the face of it, align. This misalignment ensures that systemic weaknesses can develop in the assessment process which can manifest as human failings when assessments are carried out (or not), masking the underlying system problems.

It may not be immediately apparent that the regulatory requirement for a Quality Risk Management Process is actually much more aligned with business objectives than many first believe. Risk Management strategies are now a business ‘way of life’ and are routinely incorporated in the decision making, projects and processes of successful companies.

Of course, this article could just as easily be referring to ‘why do we not do self-inspections?’ or ‘why do we not record our ad hoc training opportunities?’ and a host of other things. Sometimes laziness (or indeed other human failings) can be just that, laziness, and it should be called out for what it is. But, by only reacting to the surface level, there is a big danger of scapegoating the individual concerned and not uncovering a problem that will occur again and again.

In my experience, lack of risk assessments is a common problem. I have seen it as a GDP Inspector, as a Consultant and as a Responsible Person. You may also have seen it too. So, let’s have a look at some of the reasons why, the potential underlying cause and some thoughts that may help you resolve them.

‘I don’t have enough time’

This is so typical that it is the norm. Yes, quality staff, RPs and QPs have a massive workload.

Remember the Licence Holder is required to ensure sufficient resources for the operation. Personnel who are too busy to do the essentials are possibly under-resourced. This calls for a conversation with the Licence Holder with a focus on ensuring Quality Risk Management is given the same priority as other risk-based strategies.

On the other hand, maybe the problem presents on the surface as insufficient time but in reality the underlying cause is that the available time is not being utilised correctly. Try focusing on prioritisation or rationalising of tasks which may push risk assessments up the list.

Laziness

Almost top of the list but although a surface level problem, in my experience, not usually the underlying reason. Determining that staff are lazy is often a misinterpretation of a situation where staff are not suitably guided and maybe do not really understand the requirement. Looking for the root cause must be a key focus here.

‘I didn’t know we had to’

Section 1.5 of GDP suggests Quality Risk Management ‘should’ be done with the level of effort commensurate with the level of risk. Is this being interpreted incorrectly due to the lack of a ‘must be done’.

A little more reading on pages 60-61 and 66-70 of the Green Guide (Rules and Guidance for Pharmaceutical Distributors 2022) introduces examples that indicate the need to do this.

A useful interpretation of ‘should’, as compared to ‘must’, would be to consider all those things described as ‘should’ are to be done to remain compliant; unless there is another better way of achieving the same result.

Once again, we have a surface level problem of pleading ignorance and a search for the underlying cause will be useful.

‘I know the outcome will be bad (ie. a high risk)’

It is natural to be fearful of a bad outcome. You may see staff delaying doing the risk assessment until some remedial measures have been put in place, resulting in a risk assessment with a more palatable outcome.

Do not be tempted to put measures in place that will avoid a bad outcome without fully appraising the risk. Those measures may not be the best options and could have little effect on the risk or, worse still, increase the risk.

The best approach here is to recognise, at management level, that we have potential quality risks in distribution; in just the same way the company consider financial risks, health and safety risks, commercial risks and marketing risks. We recognise that we may have to put in considerable effort to resolve these risks. This effort needs to be carefully thought through, based on the real/potential root cause. Only a thorough risk assessment can ensure the corrective measures are appropriate.

‘I already know what is high risk and can resolve this without writing it down’

We naturally conduct risk assessments in our day-to-day activities without having to complete a record of the assessment. It can seem unnatural to then have to formalise this. This reason probably goes hand-in-hand with the previous reason ‘knowing the outcome will be bad’. It can be difficult to see our potential failings laid bare in black and white.

Remember though, that formalising a risk assessment can ensure you are clear about what you need to achieve. You now have quantifiable evidence on which to carry out your action plan. The licence holder may need to provide resource and a clearly defined and risk assessed plan will be more likely to sway the licence holder.

Again, different personalities and work methods might struggle to break the habit. This can be encouraged by the manager setting a good example. The wider use of risk management strategies in the business can make good examples.

‘I don’t know where to start’

Most of us have been there. Some develop their approach when young, such as tackling GCSE revision. Others build an effective strategy later in their career and reach their goals.

Maybe compare this with the conundrum ‘how do you eat an elephant?’. The answer is either ‘get more people to help you’ or ‘eat it one piece at a time’.

Using this type of strategy can take years to develop, especially for those who are uncomfortable asking for help or who are easily daunted by a huge workload. Setting a good example should be a key role of the manager, recognise that staff will need support for an unfamiliar task, no matter how much training they have had.

‘We don’t have a written procedure’

So, the correct response here is to write that process; but this is also not easy.

The important thing is to remember that the first draft of a process is likely to be missing some finer points. Seek help from others. Aim for a written procedure that requires processes to be examined for Critical Control Points (CCPs). Then ensure the next step is to examine those CCPs for what might go wrong; always taking into account the root cause.

Quantify the risk in terms of severity, likelihood (or frequency/probability) and how easy it would be to detect when this failure has occurred. The action plan must address the root cause and should be a workable plan.

‘The written procedure is too difficult’

As stated above, the first draft is probably not your final written procedure. Consider if you are still in this development stage. Revise the written procedure with those who will be following it.

 

Have you found some of these to be familiar reasons why you or your colleagues do not risk assess? Starting to understand the reasons why can be halfway towards solving the problem.

Resources

ICH Harmonised Guideline: Quality Risk Management Q9(R1)
ICHQ9R1
At the time of writing, this revision is still in draft.

Rules and Guidance for Pharmaceutical Distributors 2022
The MHRA have suggested a revised guide will be published in 2025. Until then, you will find this 2022 version helpful.

SeerPharmaUK one day training course – Quality Risk Management in Distribution
Quality Risk Management in Distribution course
SeerPharmaUK offer a range of training courses as well as bespoke training. Visit our training page for more details or contact us directly for more information about how we can help.

 

Learn from the people who know

SeerPharmaUK offer a range of training courses as well as bespoke training. Visit our training page for more details or contact us directly for more information about how we can help.

Nuala Calnan PhD biography

Nuala is a 25 year veteran of the pharmaceutical industry. Her work as a consultant, academic, author and commentator is directed toward the development of practical, patient-focused excellence and includes research for FDA(USA) and HPRA(Ireland) on risk surveillance, patient safety and product quality in themanufacture and distribution of drugs.

Nuala works with organizations on transforming organizational culture, delivering more effective end-to-endproactive risk management, implementing knowledge excellence strategies, behavior-based qualityexcellence and enhancing performance management through people. She is the founder of the Quality Risk

Management Institute and is currently the Co-Ordinator for the Operational Excellence Team at the Institute of Production & Supply Chain Management at St. Gallen University.

Nuala co-leads the ISPE Cultural Excellence Team, acted as Technical Author on the AdvancingPharmaceutical Quality (APQ) Guide series. At TU Dublin, Ireland, Nuala leads a number of patient focusedregulatory science research projects at Masters and PhD level and teaches on the Executive MBA (LifeSciences) on OPEX, QRM and Regulatory Science.

Professor Amira Guirguis biography

Professor Amira Guirguis is the Chief Scientist at the Royal College of Pharmacy and Professor of Pharmacy at Swansea University. A pharmacist independent prescriber, researcher and scientific leader, she works at the interface of pharmacy practice, medicines safety, research, regulation and public policy.

She is internationally recognised for her work in substance misuse, novel and emerging drugs, pharmacovigilance, harm reduction and pharmaceutical science, and has authored more than 100 scientific publications.

Amira has also pioneered the UK’s first Home Office-licensed pharmacist-led drug-checking service.

Alongside her RCPharm leadership role, Amira serves on the UK Government’s Advisory Council on the Misuse of Drugs, the General Pharmaceutical Council’s Fitness to Practise Committee, and the Pharmaceutical Society of Ireland’s Accreditation Panel.

As Chief Scientist, she leads RCPharm’s work to strengthen science and research across the profession and ensure robust evidence informs pharmacy practice, policy and innovation. Her current interests include pharmacovigilance, netnography, diversion of pharmaceuticals, and the opportunities and emerging risks associated with rapidly evolving medicines and therapeutic technologies.

Carolina Luna biography

Carolina Luna is Quality Manager and Responsible Person UK & NL at AIT Worldwide Logistics. With a career spanning pharmaceutical logistics, manufacturing and food production, she brings broad experience of applying GMP and GDP principles across regulated environments. Carolina holds a bachelor’s degree in Agro-Industrial Engineering, specialising in Food Processing.

Throughout her career, Carolina has focused on turning regulatory requirements into quality systems that work in practice. Her achievements include integrating three separate quality management systems into one, leading applications for WDA, API and MIA licences, and transitioning a paper-based QMS to an electronic platform. She has also supported regulatory inspections, conducted supplier audits, developed quality KPIs and delivered GMP/GDP training.

Carolina is currently completing a Level 4 AI and Automation Practitioner qualification and exploring practical applications of AI within pharmaceutical quality management. Through her presentation, “Practical AI for Quality and Compliance”, she aims to give quality professionals the confidence to use AI in a practical and controlled way, while reinforcing that technology should support, rather than replace, professional judgement and human oversight.

Harry Hughes biography

Harry Hughes is UK Ambassador for TAPA EMEA and Managing Director of FET Logistics Ltd. He has nearly 30 years’ experience in logistics and supply chains, specialising in secure, GDP-compliant pharmaceutical transport. His work spans quality systems, cargo crime prevention and supply chain resilience.

Stuart Tatters biography

With over 20 years in logistics, freight forwarding, and time-critical supply chains, Stuart Tatters has learned firsthand how crucial it is to know where your assets are, and where they’re going, at any given moment. In fast-moving, high-stakes environments, visibility isn’t a luxury, it’s a necessity.

That experience shapes everything he does at Sensos, where he helps organisations turn complex supply chains into responsive, efficient ecosystems through end-to-end visibility, AI-powered analytics, and smarter execution. His approach comes down to aligning people, technology, and systems; because when those three work together, you get more than a functional supply chain, you get a competitive advantage.

 

Titus Rawlins bography

A former Royal Navy Ship’s Navigator and Diver, Titus is an airline pilot of 25 years’ experience and a Human Factors Instructor who specialises in training teams who need to perform in hazardous work environments. He is qualified to deliver regulatory training to Flight Crews by the European Union Aviation Safety Administration and both the UK’s Military and Civil Aviation Authorities. 

Presenting to high performance groups and industries as diverse as Medicine and Logistics, from the UK, Europe and as far afield as Qatar and Nigeria, Titus employs a dynamic and interactive style to deliver easily relatable training models and case examples. His sessions have been proven to enhance communication and decision making, thereby minimising risk while improving efficiency, effectiveness and safety. 

Mikael Ginai biography

Mikael Ginai is Sales Director at Ginai Pharmaceuticals, helping drive a new generation of pharmaceutical wholesale.

Combining commercial leadership with a passion for technology and innovation, he has helped lead the development of Ginai’s own in-house ERP system and introduced smarter, more efficient ways of working.

His focus is on building upon the strong foundations of the pharmaceutical industry while embracing technology, innovation and new ideas to help shape its future.